These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 2253555)

  • 1. The MPTP story: MAO activates tetrahydropyridine derivatives to toxins causing parkinsonism.
    Maret G; Testa B; Jenner P; el Tayar N; Carrupt PA
    Drug Metab Rev; 1990; 22(4):291-332. PubMed ID: 2253555
    [No Abstract]   [Full Text] [Related]  

  • 2. [MPTP parkinsonism].
    Kondo T
    Ryoikibetsu Shokogun Shirizu; 1999; (27 Pt 2):37-40. PubMed ID: 10434585
    [No Abstract]   [Full Text] [Related]  

  • 3. Deuterium isotope effects for the oxidation of 1-methyl-3-phenyl-3-pyrrolinyl analogues by monoamine oxidase B.
    Pretorius A; Ogunrombi MO; Terre'blanche G; Castagnoli N; Bergh JJ; Petzer JP
    Bioorg Med Chem; 2008 Oct; 16(19):8813-7. PubMed ID: 18799315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toxins and Parkinson's disease: MPTP parkinsonism in humans and animals.
    Kopin IJ
    Adv Neurol; 1987; 45():137-44. PubMed ID: 3493621
    [No Abstract]   [Full Text] [Related]  

  • 5. [MPTP (N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) and parkinsonism].
    Gao XM; Ku BS
    Sheng Li Ke Xue Jin Zhan; 1989 Apr; 20(2):161-3. PubMed ID: 2686017
    [No Abstract]   [Full Text] [Related]  

  • 6. [Mechanism of induction of parkinsonism by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a dopaminergic neurotoxin].
    Hirata Y; Nagatsu T
    Tanpakushitsu Kakusan Koso; 1986 Apr; 31(5):398-409. PubMed ID: 3520683
    [No Abstract]   [Full Text] [Related]  

  • 7. [Clinical and biochemical parameters of parkinsonism induced by 1-methyl-4-phenyl-1,2,2,6-tetrahydropyridine and its methyl-phenyl and methoxy-phenyl derivatives in C57Bl/6 mice].
    Lermontova NN; Soliakov LS; Bachurin SO; Serkova TP; Petrova LN; Dranyĭ OA; Tkachenko SE; Kalashnikov VV
    Biull Eksp Biol Med; 1990 Oct; 110(10):397-9. PubMed ID: 2279092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of MAO in MPTP toxicity--a review.
    Glover V; Gibb C; Sandler M
    J Neural Transm Suppl; 1986; 20():65-76. PubMed ID: 3091762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of major olfactory dysfunction in MPTP-induced parkinsonism.
    Doty RL; Singh A; Tetrud J; Langston JW
    Ann Neurol; 1992 Jul; 32(1):97-100. PubMed ID: 1642478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ro 16-6491: a new reversible and highly selective MAO-B inhibitor protects mice from the dopaminergic neurotoxicity of MPTP.
    Da Prada M; Kettler R; Keller HH; Bonetti EP; Imhof R
    Adv Neurol; 1987; 45():175-8. PubMed ID: 2881442
    [No Abstract]   [Full Text] [Related]  

  • 11. Selegiline and the prophylaxis of Parkinson's disease.
    Sandler M; Willoughby J; Glover V; Gibb C
    J Neural Transm Suppl; 1987; 25():35-43. PubMed ID: 3123604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) binding sites in C57BL/6 mouse brain: mutual effects of monoamine oxidase inhibitors and sigma ligands on MPTP and sigma binding sites.
    Itzhak Y; Mash D; Zhang SH; Stein I
    Mol Pharmacol; 1991 Mar; 39(3):385-93. PubMed ID: 1848660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nitroindazole compounds inhibit the oxidative activation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxin to neurotoxic pyridinium cations by human monoamine oxidase (MAO).
    Herraiz T; Arán VJ; Guillén H
    Free Radic Res; 2009 Oct; 43(10):975-84. PubMed ID: 19669997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MPTP- but not methamphetamine-induced parkinsonism extends to catecholamine neurons in the gut.
    Natale G; Kastsiuchenka O; Pasquali L; Ruggieri S; Paparelli A; Fornai F
    Ann N Y Acad Sci; 2008 Oct; 1139():345-9. PubMed ID: 18991880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of fluorinated 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine analogs with potent nigrostriatal toxicity for potential use in positron emission tomography studies.
    Harik SI; Riachi NJ; Hritz MA; Berridge MS; Sayre LM
    J Pharmacol Exp Ther; 1993 Aug; 266(2):790-5. PubMed ID: 8355208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-activity study of the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity. I. Evaluation of the biological activity of MPTP analogs.
    Youngster SK; Sonsalla PK; Sieber BA; Heikkila RE
    J Pharmacol Exp Ther; 1989 Jun; 249(3):820-8. PubMed ID: 2786564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): one designer drug and serendipity.
    Weingarten HL
    J Forensic Sci; 1988 Mar; 33(2):588-95. PubMed ID: 3259617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Parkinsonism and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (review of the literature)].
    Atadzhanov MA
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1991; 91(4):117-21. PubMed ID: 1650080
    [No Abstract]   [Full Text] [Related]  

  • 19. MPTP: a pharmacological tool to study parkinsonism.
    Kulkarni SK; Mehta AK; Aley KO; Shukla VK
    Methods Find Exp Clin Pharmacol; 1986 Aug; 8(8):485-9. PubMed ID: 3489146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The bases of MPTP neurotoxicity].
    Dostert P; Strolin Benedetti M
    Encephale; 1988; 14(6):399-412. PubMed ID: 3068045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.